<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02184013</url>
  </required_header>
  <id_info>
    <org_study_id>20140623</org_study_id>
    <nct_id>NCT02184013</nct_id>
  </id_info>
  <brief_title>Correlation of the Arrhythmia Mechanism and Substrate to Ablate Persistent Atrial Fibrillation Study</brief_title>
  <acronym>COAST-AF</acronym>
  <official_title>Correlation of Arrhythmia Mechanism and Substrate to Ablate Persistent Atrial Fibrillation:A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Heart Institute Research Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ottawa Heart Institute Research Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study to assess the usefulness of ECG mapping, and enhanced MRI and PET scan&#xD;
      imaging in identifying atrial fibrosis and arrhythmia circuits involved in persistent atrial&#xD;
      fibrillation and in guiding an innovative AF catheter ablation strategy.&#xD;
&#xD;
      It is hypothesized that identifying these critical arrhythmia circuits and atrial fibrosis&#xD;
      with enhanced imaging and performing an individualized innovative AF catheter ablation will&#xD;
      result in higher procedural success rates.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pulmonary vein isolation catheter ablation for the treatment of persistent AF (PeAF)or&#xD;
      longstanding persistent AF is associated with success rates of 40-50% at one year.&#xD;
      Experimental models have shown that AF results in progressive structural changes due to&#xD;
      electrical atrial remodeling, where AF burden correlates with atrial fibrosis. The optimal&#xD;
      ablation strategy for patients with PeAF is not yet known. There is limited understanding of&#xD;
      the critical mechanisms responsible for maintenance of AF in these patients.&#xD;
&#xD;
      In this study ECG body mapping (ECGI) will be used to look for distinct electrical rotors in&#xD;
      the atria. Delayed gadolinium enhanced magnetic resonance imaging (DE-MRI) will be used to&#xD;
      assess the extent of left atrial fibrosis. In addition to PVI catheter ablation procedure, an&#xD;
      ablation strategy guided by the results of the ECGI mapping and DE-MRI will be performed.A&#xD;
      C-metahydroxyepherdrine (HED) PET scan will also be done pre-ablation to evaluate left atrial&#xD;
      sympathetic denervation and any relationship to the initiation and/or maintenance of AF.&#xD;
&#xD;
      Subjects will be seen at 3 and 6 months after ablation, with 12 lead ECG and 2-week loop&#xD;
      monitoring done at each visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Atrial Fibrillation (AF) Termination</measure>
    <time_frame>During catheter ablation</time_frame>
    <description>AF termination resulting in restoration of sinus rhythm during ablation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radio frequency (RF) ablation time</measure>
    <time_frame>During catheter ablation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure Duration</measure>
    <time_frame>During catheter ablation</time_frame>
    <description>Total procedure duration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from AF</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">52</enrollment>
  <condition>Persistent Atrial Fibrillation</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Catheter ablation</intervention_name>
    <description>Catheter ablation (in addition ot PVI) guided by ECGI mapping, and atrial fibrosis mapping (DE-MRI).</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years and ≤ 80 years;&#xD;
&#xD;
          -  Symptomatic persistent AF AND clinically indicated for AF catheter ablation&#xD;
&#xD;
          -  At least one episode of AF lasting more than 7 days, documented on 12-lead ECG, Holter&#xD;
             monitor, 2-week loop monitor or trans-telephonic monitor (TTM) within 12 months of&#xD;
             enrollment in the study&#xD;
&#xD;
          -  Able to provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of previous catheter or surgical ablation for AF&#xD;
&#xD;
          -  Presence of intracardiac thrombus&#xD;
&#xD;
          -  contraindication to systemic oral anticoagulation therapy&#xD;
&#xD;
          -  Subjects with reversible causes of AF&#xD;
&#xD;
          -  Antero-posterior left atrial dimension &gt; 60 mm on echocardiography&#xD;
&#xD;
          -  Severe valvular disease (mitral/aortic stenosis or regurgitation);&#xD;
&#xD;
          -  Subjects that are pregnant or breastfeeding;&#xD;
&#xD;
          -  Chronic kidney disease and creatinine clearance &lt;50ml/min.&#xD;
&#xD;
          -  Contraindication to MRI Imaging (e.g. permanent pacemaker, metallic implants, etc)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pablo B Nery, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Heart Institute Research Corporation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert deKemp, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Heart Institute Research Corporation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elena Pena, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Ottawa Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David H Birnie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Heart Institute Research Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>July 2, 2014</study_first_submitted>
  <study_first_submitted_qc>July 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <last_update_submitted>November 11, 2020</last_update_submitted>
  <last_update_submitted_qc>November 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Catheter ablation</keyword>
  <keyword>Delayed gadolinium enhanced MRI</keyword>
  <keyword>C-metahydroxyepherdrine (HED) PET scan</keyword>
  <keyword>ECGI mapping</keyword>
  <keyword>Atrial Fibrosis</keyword>
  <keyword>Atrial sympathetic denervation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

